Gene therapy strategies: can we eradicate HIV? (Q34165454)

31 July 2017

title

Gene therapy strategies: can we eradicate HIV? (English)

1 reference

31 July 2017

0 references

1

Jan van Lunzen

1 reference

31 July 2017

2

Boris Fehse

1 reference

31 July 2017

Joachim Hauber

3

1 reference

31 July 2017

publication date

1 June 2011

1 reference

31 July 2017

published in

Current HIV/AIDS reports

1 reference

31 July 2017

volume

8

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

78-84

1 reference

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Genetic therapies against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Semen-derived amyloid fibrils drastically enhance HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Impact of gene-modified T cells on HIV infection dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Gene therapy. Intracellular immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Deciphering the code for retroviral integration target site selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Side effects of retroviral gene transfer into hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Physiological promoters reduce the genotoxic risk of integrating gene vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Resistance of mature T cells to oncogene transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Targeted genome modifications using integrase-deficient lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Insertional mutagenesis and clonal dominance: biological and statistical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Gene therapy for HIV infection: what does it need to make it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

HIV-1 proviral DNA excision using an evolved recombinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Conditional control of gene expression in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

Talking about a Revolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-011-0073-9

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

21 January 2018

1 reference

12 December 2020

Virological rebound and its consequences during treatment interruption

1 reference

12 December 2020

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

1 reference

12 December 2020

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation

1 reference

12 December 2020

How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.

1 reference

12 December 2020

Gene therapy for HIV infection

1 reference

12 December 2020

A third-generation lentivirus vector with a conditional packaging system

1 reference

12 December 2020

Genotoxicity in gene therapy: an account of vector integration and designer nucleases.

1 reference

12 December 2020

Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen

1 reference

12 December 2020

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial

1 reference

12 December 2020

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

1 reference

12 December 2020

Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice

1 reference

12 December 2020

10.1007/S11904-011-0073-9

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1049684581

0 references

1 reference